Session

IBD (Posters)

IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT
IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT

IBD (Posters)  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

IBD (Posters)  et al.

ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE
ADALIMUMAB 80MG EVERY OTHER WEEK IN INFLAMMATORY BOWEL DISEASE: TREATMENT INTENSIFICATION OUTCOMES IN REAL LIFE CLINICAL PRACTICE

IBD (Posters)  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

IBD (Posters)  et al.

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA

IBD (Posters)  et al.

PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING
PRACTICAL DEEP LEARNING TOOL FOR SCORING OF ULCERATIVE COLITIS DISEASE ACTIVITY IN CENTRAL READING

IBD (Posters)  et al.

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

IBD (Posters)  et al.

THE NATURAL DISEASE COURSE OF CROHN’S DISEASE IN A DANISH POPULATION-BASED INCEPTION COHORT WITH MORE THAN FIFTY YEARS OF FOLLOW-UP
THE NATURAL DISEASE COURSE OF CROHN’S DISEASE IN A DANISH POPULATION-BASED INCEPTION COHORT WITH MORE THAN FIFTY YEARS OF FOLLOW-UP

IBD (Posters)  et al.

EFFECTS OF COVID-19 ON TREATMENT AND PATIENT MANAGEMENT IN INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE
EFFECTS OF COVID-19 ON TREATMENT AND PATIENT MANAGEMENT IN INFLAMMATORY BOWEL DISEASE: FINDINGS FROM A REAL-WORLD SURVEY IN EUROPE

IBD (Posters)  et al.

SERUM INFLIXIMAB CONCENTRATIONS DURING INDUCTION PREDICT SHORT-TERM TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SERUM INFLIXIMAB CONCENTRATIONS DURING INDUCTION PREDICT SHORT-TERM TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU
LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU

IBD (Posters)  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

IBD (Posters)  et al.

REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE
REAL WORLD EXPERIENCE OF SWITCHING INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB AS MAINTENANCE TREATMENT FOR INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

CHROMOENDOSCOPY FOR DETECTING DYSPLASIA IN IBD PATIENTS: PRELIMINARY RESULTS FROM A SINGLE-CENTRE, PROSPECTIVE OBSERVATIONAL STUDY
CHROMOENDOSCOPY FOR DETECTING DYSPLASIA IN IBD PATIENTS: PRELIMINARY RESULTS FROM A SINGLE-CENTRE, PROSPECTIVE OBSERVATIONAL STUDY

IBD (Posters)  et al.

REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY
REAL-LIFE EVALUATION OF GOLIMUMAB EFFECTIVENESS AND QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: THE PROSPECTIVE GO-CARE STUDY

IBD (Posters)  et al.

PATHOLOGIC INVOLVEMENT OF THE FARNESOID X RECEPTOR/FIBROBLAST GROWTH FACTOR 19 AXIS TO THE CROHN’S DISEASE EARLY POSTSURGICAL RECURRENCE
PATHOLOGIC INVOLVEMENT OF THE FARNESOID X RECEPTOR/FIBROBLAST GROWTH FACTOR 19 AXIS TO THE CROHN’S DISEASE EARLY POSTSURGICAL RECURRENCE

IBD (Posters)  et al.

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE
OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

IBD (Posters)  et al.

A TERTIARY MULTICENTER COHORT OF PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND CROHN’S DISEASE: A RARE ASSOCIATION WITH A HIGH PREVALENCE OF MONOGENIC DISORDERS
A TERTIARY MULTICENTER COHORT OF PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND CROHN’S DISEASE: A RARE ASSOCIATION WITH A HIGH PREVALENCE OF MONOGENIC DISORDERS

IBD (Posters)  et al.

OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY
OUTCOMES OF EARLY AND LATE ADVANCED THERAPY USE IN PATIENTS WITH ULCERATIVE COLITIS: FINDINGS FROM A EUROPEAN REAL-WORLD STUDY

IBD (Posters)  et al.

THE NATURAL DISEASE COURSE OF ULCERATIVE COLITIS IN A DANISH POPULATION-BASED INCEPTION COHORT WITH MORE THAN FIFTY YEARS OF FOLLOW-UP
THE NATURAL DISEASE COURSE OF ULCERATIVE COLITIS IN A DANISH POPULATION-BASED INCEPTION COHORT WITH MORE THAN FIFTY YEARS OF FOLLOW-UP

IBD (Posters)  et al.

Item 321 - 340 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
17
18 19 20 21 22 23 24 25 26 27 28 29